



VacZine Analytics

Bringing life to vaccine strategy...

DiseaseINFOPACK

Community-acquired MRSA

May 2008

Abstract

DiseaseINFOPACK: *Community-acquired MRSA*

CAT No: VADIP003, published October 2007

REPORT ABSTRACT:

Community-acquired methicillin resistant *Staphylococcus aureus* (CA-MRSA) has clinical, epidemiologic and bacteriologic characteristics that are distinct from the hospital-acquired form of the pathogen (HA-MRSA). Of most concern to healthcare stakeholders is that the pathogen can cause severe disease in previously healthy persons with no history of contact with the hospital setting. CA-MRSA is transmitted from person-to-person with disease outbreaks being reported in competitive sportsmen, inmates and day-care attendees. This **DiseaseINFOPACK** report is an expert review of the current literature providing the reader with a full easy-to-read overview of the pathogen, its epidemiology, through to its clinical and economic impact. The report places a focus on recognition, treatment and future dynamics of the pathogen. It also includes opinion and comment from global experts.

PAGES: 44

Table of contents

Executive Summary
Author's Note
The Pathogen
Methicillin-resistant *S.aureus* (MRSA)
Characteristics of CA-MRSA
Expert Viewpoints: CA-MRSA
CA-MRSA 300 and 4000
Transmission of CA-MRSA
Pathogenesis
Proteins involved in *S.aureus* pathogenesis
Host Response
Risk Factors for CA-MRSA infection
Risk Groups for CA-MRSA infection
Expert Viewpoints: Risk factors for CA-MRSA
Prevention and Control
Diagnosis
Clinical assessment
Clinical Outcome
Expert Viewpoints: Clinical Outcome

Pathology
Treatment of MRSA Skin Lesions (1)
Comparison of agents for CA-MRSA
Treatment of MRSA Skin Lesions (2)
Expert Viewpoints: Treatment of CA-MRSA
Morbidity/Mortality
Epidemiology – Surveillance
Epidemiology – Incidence/Prevalence (1)
Epidemiology – Incidence/Prevalence (2)
Expert Viewpoints: Outlook for CA-MRSA
Economic Impact
Disease Trends and Dynamics
Opportunity For New Treatments
Appendix I – Back-up
Appendix II – Bibliography
Appendix III – About VacZine Analytics

Bibliography

1. US Centers for Disease Control and Prevention. Community-Associated MRSA Information for the Public. Available at http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca_public.html. Accessed May 2008.
2. Shinefield H., et al. Use of *Staphylococcus aureus* conjugate vaccine in patients receiving hemodialysis (2002). NEJM 346:491-496
3. Jevons MP. Celbenin – resistant *Staphylococci*. BMJ 1961; 1:124-5
4. Utsui Y., et al. Role of an altered penicillin-binding protein in methicillin and cephem resistant *Staphylococcus aureus* (1985). Antimicrob Agents Chemother 28:397-403.
5. US Centers for Disease Control and Prevention. Strategies for Clinical Management of MRSA in the community. Summary of Experts Meeting. March 2006. Accessed September 2007.
6. McDougal LK., et al. Pulsed-Field gel electrophoresis typing of Oxacillin-resistant *Staphylococcus aureus* isolates from the United States: Establishing a national database (2003). J Clin Microbiol. 41: 5113-20
7. Kazakova SV., et al. A clone of methicillin-resistant *Staphylococcus aureus* among professional football players (2005). NEJM. 352:28-35
8. Centers for Disease Control and Prevention. Methicillin-resistant *Staphylococcus aureus* infection in correctional facilities 2001-2003. MMWR Morb Mortal Wkly Rep. Oct 2001; 50 (42):919-922
9. Baggett HC., et al., Community-onset methicillin-resistant *Staphylococcus aureus* associated with antibiotic use and the cytotoxin Panton-Valentine Leukocidin during a furunculosis outbreak in rural Alaska (2004). J Infect Dis. 189 (9);1565-1573
10. eMedicine (www.emedicine.com). *Staphylococcus aureus* Infection. Article by Robert W Tolan. Updated 31 May 2007. Available at: <http://www.emedicine.com/ped/topic2704.htm>. Accessed September 2007
11. *S.aureus* vaccine development. Presentation by Jean C Lee. Channing Laboratory. Brigham and Women's Hospital. Harvard Medical School. Available at: http://www.secebt.org/uploads/documents/Lee_MRSA.ppt. Accessed September 2007.
12. Fridkin SK., et al., Methicillin-resistant *Staphylococcus aureus* disease in three communities (2005). NEJM 352:1436-1444
13. Centers for Disease Control and Prevention. Community-associated methicillin resistant *Staphylococcus aureus* in Pacific Islanders Hawaii 2001 (2003) MMWR Morb Mortal Wkly Rep 52(5):88
14. Ellis MW., et al., Natural History of community-acquired methicillin-resistant *Staphylococcus aureus* colonization and infection in soldiers (2004). Clin Infect Dis. 39(7):971-979
15. Centers for Disease Control and Prevention. Four Pediatric Deaths from CA-MRSA: Minnesota and North Dakota, 1997-1999 (1999) MMWR Morb Mortal Wkly Rep 48(32):707-710
16. US Centers For Disease Control and Prevention. Laboratory Detection of: Oxacillin/Methicillin-resistant *Staphylococcus aureus* (2005). Available at: http://www.cdc.gov/ncidod/dhqp/ar_lab_mrsa.html. Accessed May 2008.
17. **Adapted from:** Nathwani D., et al., Guidelines for UK practice for the diagnosis and management of methicillin-resistant *Staphylococcus aureus* (MRSA) Infections presenting in the community. J. Antimicrobial Chemo (2008) 61: 976-994
18. Hardy KJ., et al. Methicillin resistant *Staphylococcus aureus* in the critically ill (2004). Brit Journal Anesth. 92 (1)121-130
19. APUA website. Update on antibiotic-resistant *Staph aureus* – new threats in the community. Available at: <http://www.tufts.edu/med/apua/print/mrsa/mrsa.html>. Accessed May 2008
20. Hageman JC., et al. Severe community-acquired pneumonia due to *Staphylococcus aureus*, 2003-04 Influenza Season (2006). Emer Inf Dis. 12: 894-899

Bibliography (cont..)

21. Cookson BD., et al. MRSA in the community: new battlefronts, or are the battles lost? (2000) *Infect Control Hosp Epidemiol.* 21:398-403
22. Centers For Disease Control and Prevention (CDC). MRSA Skin or Soft Tissue Infections in a State Prison – Mississippi, 2000 *MMWR Morb Mortal Wkly Rep* 50(42):919-922
23. Health Protection Agency. Guidance on the diagnosis and management of PVL-associated *Staphylococcus aureus* infections (PVL-SA) in the UK. Currently undergoing consultation. [Http://www.hpa.rog.uk/consultations/2008/pvl.htm](http://www.hpa.rog.uk/consultations/2008/pvl.htm). Accessed February 2008
23. Lina G., et al. Involvement of Panton-Valentine Leukocidin-producing *Staphylococcus aureus* in primary skin infections and pneumonia (2003) *J Clin Infect Dis.* 29:1128-1132
24. Keuhnert MJ., et al. Prevalence of *Staphylococcus aureus* Nasal colonization in the United States. 2001-2002 (2006) *J Infect Dis.* 193:172-179
25. Wenzel RP., et al. The significance of nasal carriage of *S.aureus* and the incidence of postoperative wound infection (1995). *J Hosp Infect.* 31:13-2
26. Salgado CD., et al. Community-acquired methicillin-resistant *S.aureus*: a meta-analysis of prevalence and risk factors. *Clin Infect Dis* 2003; 36: 131-9

27. Naimi TS et al., Epidemiology and clonality of community-acquired MRSA in Minnesota (2001) *Clin Infect Dis.* 33:990-996
28. Purcell K., et al. Economic Impact of the CA-MRSA epidemic on the Driscoll's Children's Health Plan (2006). *Ped Inf Dis J.* 25:178-80
29. EARSS. Annual Report 2005. Chapter 3. Antimicrobial resistance in Europe. Available at: <http://www.rivml.nl/earss/images/EARSS>. Accessed September 2007
30. Creech CB., et al. Increasing rates of nasal carriage of MRSA in healthy children (2005). *Ped Inf Dis. J* 24:617-621
31. CA-MRSA: An Emergent Pathogen. Presentation by M.Hull. September 2006. Available at: http://www.cshp-bc.com/events/2006%20Events/Clinical_Symposium/mhmrna.pdf . Accessed May 2008.
32. Saiman L., et al. Hospital transmission of community-acquired methicillin-resistant *S.aureus* among postpartum women (2003). *Clin Infect Dis.* 10:1313-1319
33. Han LL., et al. High Frequencies of Clindamycin and Tetracycline Resistance in Methicillin-Resistant *Staphylococcus aureus* Pulsed-Field Type USA300 Isolates Collected at a Boston Ambulatory Health Center *J Clin Micro* April 2007, p. 1350-1352, Vol. 45, No. 4



About VacZine Analytics:

VacZine Analytics is a brand new research consultancy based in the United Kingdom. Its aim is to provide high-quality disease and commercial analysis to those working within or in collaboration with the vaccine industry.

With our product lines:

- DiseaseINFOPACK
- OpportunitySCAN
- MarketVIEW
- ExpertREACT
- VaccineSTATS

Our key focus is helping clients to build the case for developing new vaccines.



VacZine Analytics

Bringing life to vaccine strategy...

www.vacZine-analytics.com

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel. +44 (0) 1279 654514

e-mail: info@vacZine-analytics.com

© VacZine Analytics, 2008. All rights reserved.